Literature DB >> 21262356

A novel cross-talk between endothelin-1 and cyclic AMP signaling pathways in the regulation of GLUT1 transcription in 3T3-L1 adipocytes.

Ying-Shiun Kao1, Jim C Fong.   

Abstract

We showed previously that chronic exposure to both endothelin-1 (ET-1) and cAMP resulted in a synergistic increase in Glut1 transcription in 3T3-L1 adipocytes via a protein kinase C (PKC)-dependent mechanism. In the present study, we further examined the molecular mechanism involved. Employing transient transfections with Glut1 promoter/enhancer -luciferase reporter and several dominant negative or constitutively active PKC mutants, we identified PKCε as the responsible PKC. Investigation with deletion and mutation mutants of the promoter/enhancer reporter suggested that Sp1, CREB and AP-1 responsive elements on enhancer 2 were involved. Furthermore, chromatin immunoprecipitation and co-immunoprecipitation analysis were applied to characterize the interactions between these transcription factors and their bindings to enhancer 2 in vivo. The results indicate that there are both negative and positive interactions between ET-1 and cAMP signaling pathways. On the one hand, cAMP inhibits ET-1 induced NF-κB activation required for ET-1-stimulated Glut1 transcription; on the other hand, cAMP, via sustained CREB phosphorylation, may activate AP-1 and cooperate with ET-1-activated PKCε to enhance Sp1 expression and consequently to generate a stable enhancer 2-bound Sp1/pCREB/AP-1 complex, which can strongly facilitate Glut1 transcription more than the additive effect of ET-1 and cAMP alone.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21262356     DOI: 10.1016/j.cellsig.2011.01.016

Source DB:  PubMed          Journal:  Cell Signal        ISSN: 0898-6568            Impact factor:   4.315


  5 in total

1.  Marked, homogeneous, and early [18F]fluorodeoxyglucose-positron emission tomography responses to vemurafenib in BRAF-mutant advanced melanoma.

Authors:  Grant A McArthur; Igor Puzanov; Ravi Amaravadi; Antoni Ribas; Paul Chapman; Kevin B Kim; Jeffrey A Sosman; Richard J Lee; Keith Nolop; Keith T Flaherty; Jason Callahan; Rodney J Hicks
Journal:  J Clin Oncol       Date:  2012-03-26       Impact factor: 44.544

2.  m6A methylation mediates LHPP acetylation as a tumour aerobic glycolysis suppressor to improve the prognosis of gastric cancer.

Authors:  Jian-Xian Lin; Ning-Zi Lian; You-Xin Gao; Qiao-Ling Zheng; Ying-Hong Yang; Yu-Bin Ma; Zhi-Song Xiu; Qing-Zhu Qiu; Hua-Gen Wang; Chao-Hui Zheng; Ping Li; Jian-Wei Xie; Jun Lu; Qi-Yue Chen; Long-Long Cao; Mi Lin; Jia-Bin Wang; Chang-Ming Huang
Journal:  Cell Death Dis       Date:  2022-05-14       Impact factor: 9.685

Review 3.  Precision Medicine and PET/Computed Tomography in Melanoma.

Authors:  Esther Mena; Yasemin Sanli; Charles Marcus; Rathan M Subramaniam
Journal:  PET Clin       Date:  2017-07-14

4.  Direct action of endothelin-1 on podocytes promotes diabetic glomerulosclerosis.

Authors:  Olivia Lenoir; Marine Milon; Anne Virsolvy; Carole Hénique; Alain Schmitt; Jean-Marc Massé; Yuri Kotelevtsev; Masashi Yanagisawa; David J Webb; Sylvain Richard; Pierre-Louis Tharaux
Journal:  J Am Soc Nephrol       Date:  2014-04-10       Impact factor: 10.121

5.  A first-in-human phase I, multicenter, open-label, dose-escalation study of the oral RAF/VEGFR-2 inhibitor (RAF265) in locally advanced or metastatic melanoma independent from BRAF mutation status.

Authors:  Benjamin Izar; William Sharfman; F Stephen Hodi; Donald Lawrence; Keith T Flaherty; Ravi Amaravadi; Kevin B Kim; Igor Puzanov; Jeffrey Sosman; Reinhard Dummer; Simone M Goldinger; Lyhping Lam; Shefali Kakar; Zhongwen Tang; Oliver Krieter; David F McDermott; Michael B Atkins
Journal:  Cancer Med       Date:  2017-07-18       Impact factor: 4.452

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.